Fighting HIV/AIDS around the world
“For me, it all came together at the World AIDS conference in 2018. That’s where we showed the best of Amsterdam and the Netherlands in the HIV and AIDS community.” We’re sat on an upper-level floor of a Zuidas tower block and Gilead’s head of external affairs Martijn Groot is recalling a special moment in his career. “We received the ‘positive flame’ from French virologist Françoise Barré-Sinoussi. That was a moment I felt especially proud of the work that we do.”
For those that know about Gilead’s work in HIV/AIDS, Groot’s choice of the AIDS Conference 2018 should come as no surprise. For more than a decade, it has been a leader in the development of antiretroviral therapy for HIV/AIDS. As well as developing 11 commercially available HIV medications, the firm continues to research and develop a robust pipeline of next-generation therapeutic options. It also supports organisations that help with the stigmas around HIV, such as addiction.
The Gilead team await the ‘positive flame’ at AIDS 2018
“We’re getting to a phase with HIV that individuals are living like anyone else would without the disease,” explains Sabrina Barbic, Gilead’s general manager in the Netherlands, “Our business is about HIV. That’s our legacy, and I am so proud to be part of that. We continue to invest in this disease until it is cured. We’ve come so far but we keep going - keeping it at the forefront of people’s minds.”
Developing treatments for life-threatening diseases
Gilead’s mission is to find treatments – ideally cures - for areas of high unmet medical need. The company is built on three pillars: science, access and partnership. Through its Access to Medicines programmes, it is also supporting front-line services and care in more than 140 low- and middle-income countries.
“Gilead was one of the first companies to put its patents in a world-wide patent pool so people in developing countries all over the world could have access to treatments without price getting in the way,” explains Barbic. “I think our core values are around integrity and doing the right thing. Even today all our new medications go straight into that patent pool to again provide broader access in developing countries.”
Why Gilead chose Amsterdam
Gilead established itself in the Amsterdam Area 12 years ago, starting out with just three employees. Now its team in the Dutch capital is more than 40-strong, and includes medical, commercial, supply, logistics, regulatory, and management staff.
“The decision to come to Amsterdam was easy,” explains Barbic. “We were attracted by the city’s close vicinity to Amsterdam Airport Schiphol and infrastructure, and the fact that many of the world-renowned researchers in HIV are based in Amsterdam.”
As well as Gilead’s own office, Kite, a Gilead company, is also one of the Amsterdam’s many life science organisations. It is developing signature T-cell-based immunotherapy treatments that reprogrammes patients’ own cells to fight cancer, arming the immune system with the tools to target and attack cancer cells from within.
“logistical advantages are also really important, and Amsterdam provides a great hub in Europe for that,” explains Barbic. “In terms of Kite’s new production facility, being based in Amsterdam means we can reduce the time it takes for European patients to get their personalised therapy. It’s so convenient.”
The good life in Amsterdam
After living in Amsterdam for just over a year, Australian-born Barbic has only good things to say about life in the city: “It’s been a wonderful first-year experience. Having also lived in France, the UK, the US and Australia, Amsterdam provides internationals with incredible diversity. And, on a personal level, it provides all the good stuff that a larger city can provide. When you’re getting around it gives you a sense that it’s a much smaller city. That makes it a very easy place to live. And that’s a common feeling in the international community.”
Gilead and Galapagos: Creating new opportunities
Looking to the future, Gilead continues working towards improving the lives of the patients who use its medicines and developing new therapeutics to fight against life-threatening diseases. One thing that will help it do that is the $5.1 billion (€4.5 billion) partnership deal it signed with Belgian-Dutch biotech company Galapagos last year. “The essence of the Galapagos deal is retaining independence and enhancing development,” explains Barbic. “It’s quite a unique collaboration in the pharma world: It’s a deal that benefits both sides, but most importantly, patients and science.”
“Groot says the Amsterdam Area is on its way to becoming a world-leading hub. It has Schiphol, two academic medical centres, and one of the world’s leading cancer centres: the Science Park.” Barbic, however, has concerns that the Dutch government putting too much focus on the price and costs of medicines, instead of looking at the actual value for patients. “This is the antithesis of innovation. We’re constantly bringing in new, better medications for patients, which comes with a lot of investment. We aim to secure broad access to our products in a sustainable manner, both for us and Dutch society.”
Ultimately, the focus of our time together is on helping patients. As we near the end of our chat, Barbic reveals a moment which she says reminded her of the good Gilead does. “In Australia I met a neighbour and we got talking for the first time,” she says. “She disclosed to me that she had been diagnosed with Hepatitis C and our treatment had cured her. As a result, she was moving her whole family to somewhere nice and sunny and had a whole new lease of life. I walked away from that encounter realising the impact our work can have on people’s lives.”
Read more business news from around Amsterdam.